 CAMBRIDGE, Mass., March 17, 2021 GLOBE NEWSWIRE -- Solid Biosciences Inc., Nasdaq: SLDB a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy Duchenne, today announced that it has commenced an underwritten public offering of 85 million of shares of its common stock. All of the shares are being offered by Solid. In addition, Solid expects to grant the underwriters a 30-day option to purchase up to an additional 15 of the shares of its common stock sold in the public offering on the same terms and conditions. 